ABVX:EPA
Abivax SA
€83.85
0.00%
(0.00) 1 天
9月29日, GMT+2 17:35:35 · EUR
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 ABVX 生成关键数据洞见…
开盘价
€84.35
最高价
€86.45
最低价
€83.60
市值
73.03亿
平均成交量
14.95万
成交量
13.38万
52 周最高价
€139.00
52 周最低价
€60.45
每股收益
-€5.20
流通股数
8735.00万
员工人数
98
开盘价
€84.35
最高价
€86.45
最低价
€83.60
市值
73.03亿
平均成交量
14.95万
成交量
13.38万
52 周最高价
€139.00
52 周最低价
€60.45
每股收益
-€5.20
流通股数
8735.00万
员工人数
98
新闻报道
来自网络来源和新闻合作伙伴
Timothy Sykes
·
22小时前
ABVX Stock Draws Bullish Targets As Obefazimod Momentum Builds
Timothy Sykes
·
1天前
ABVX Stock Gains Traction As Obefazimod Story Strengthens
MarketBeat
·
1天前
Abivax (NASDAQ:ABVX) Shares Climb 4.4% - Should You Buy?
Ideal Investisseur
·
1天前
Abivax share falls below €81.45, RSI in extreme oversold territory
资料
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA简介